Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

267 results about "Cell immune response" patented technology

An immune response is a two-way assault on a pathogen – the cell mediated immune response and the humoral immune response. Cell mediated immune response is carried out by the T-cells or T lymphocytes (Fig. 11). So, it is also called T-cell immunity. This type of immune response is to defend against pathogens that may invade host cells.

MRNA (messenger ribonucleic acid) vaccine and application thereof in preparing medicine for treating tumors

The invention provides an mRNA (messenger ribonucleic acid) vaccine and application of the mRNA vaccine in preparation of a medicine for treating tumors. The vaccine consists of ionizable lipid, cholesterol, phospholipid, a PEG (Polyethylene Glycol) derivative and mRNA (Messenger Ribonucleic Acid) containing a gene sequence for coding norovirus S protein fusion tumor antigen or a gene sequence for coding tumor antigen fusion ferritin. According to the mRNA vaccine designed by the invention, the antigen expression quantity is increased, a nanocrystallization antigen structure is formed to promote antigen processing and presentation, strong anti-tumor cell immune response is stimulated, and a tumor local microenvironment is effectively remodeled, so that a remarkable tumor inhibition effect is achieved.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Composite vaccine adjuvant as well as preparation method and application thereof

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.
Owner:CHANGSHA NUO MENG BIOMEDICAL CO LTD

Gene for coding Marburg virus glycoprotein, related mRNA molecule and application thereof

The invention belongs to the technical field of nucleic acid vaccines, and particularly relates to a coding gene of Marburg virus glycoprotein, a related mRNA (messenger Ribonucleic Acid) molecule and application thereof. The nucleotide sequence of the gene is as shown in SEQ ID NO.1. A DNA vaccine for preventing Marburg virus is prepared from a vector containing the gene. A transcription template DNA (deoxyribonucleic acid) sequence of the mRNA molecule is shown as SEQ ID NO.2, all uridine in the mRNA molecule is replaced by N1-methyl-pseudouridine-5 '-triphosphate, and the mRNA vaccine for preventing the Marburg virus is prepared by utilizing the mRNA molecule. When the DNA vaccine and the mRNA vaccine are used for immunizing animals (BALB / c mice) for immunological evaluation, it is proved that candidate nucleic acid vaccines can induce antigen-specific body fluid and cellular immune response of immunized mice, and the potential of novel MARV nucleic acid vaccines in preventing Marburg virus diseases is proved.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Combination exosome immunogenic compositions and methods

The present disclosure relates to compositions and methods for vaccinating a subject against a variety of SARS-CoV-2 variants and other respiratory viruses, the compositions and methods involve preparing and delivering extracellular vesicles expressing on its surface an engineered spike protein, an engineered nucleocapsid protein, an engineered hemagglutinin protein, and / or an engineered respiratory syncytial virus pre-fusion or fusion (RSV F) protein. The invention also relates to compositions and methods for designing, preparing, making, formulating and / or using spike display, nucleocapsid display, hemagglutinin display and / or RSV F display vesicle vaccines, the spike display, nucleocapsid display, hemagglutinin display, and / or RSV F display vesicle vaccines are designed to elicit potent humoral and cellular immune responses against a variety of respiratory viruses and variants.
Owner:CAPRICOR INC

Recombinant vaccine against COVID-19 based on a paramyxovirus viral vector

An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and / or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-COV-2 exogenous nucleotide sequence inserted.
Owner:MT SINAI SCHOOL OF MEDICINE +1

Inactivated bacterial preparation as well as preparation method and application thereof

The invention provides an inactivated bacterial preparation as well as a preparation method and application thereof. According to the method, the manganese-containing oxidizing agent and bacterial pathogens are incubated, and the purpose of inactivating bacteria is achieved within a short time by utilizing the strong oxidizing property of the manganese-containing oxidizing agent; and slowly dripping a polyphenol monomeric compound solution into the system, self-polymerizing on the surface of the bacteria under the action of the manganese-containing oxidizing agent, reducing the manganese-containing oxidizing agent to form a manganese adjuvant, attaching the manganese adjuvant to the surface of the bacteria, and simultaneously loading the manganese adjuvant on the surface of the bacteria. The method is suitable for various bacteria and polyphenol monomers. The prepared inactivated bacterial preparation can effectively induce humoral immunity and cellular immunity response of antigen specificity and effectively protect bacterial infection, and has wide application prospects in antibacterial vaccines and vaccine adjuvants.
Owner:SICHUAN UNIV

Porcine rotavirus VP7 multi-epitope fusion protein as well as preparation method and application thereof

The invention discloses a porcine rotavirus VP7 protein conservative dominant B cell antigen epitope peptide or a combination thereof or a nucleic acid molecule and application thereof, and further discloses a porcine rotavirus VP7 protein multi-epitope fusion protein and a preparation method and application thereof. The multi-epitope fusion protein disclosed by the invention not only can induce high-level specific antibody response and cellular immune response aiming at the VP7 protein and effectively inhibit porcine rotavirus infection, but also has relatively high safety and stability. Compared with the traditional fusion protein, the multi-epitope fusion protein disclosed by the invention has remarkable advantages in the aspects of production cost, immune efficacy and the like, and a feasible porcine rotavirus prevention and control scheme is provided for the pig industry.
Owner:YANGZHOU UNIV

African swine fever virus T cell epitope peptide for inducing swine T cell immune response and application of African swine fever virus T cell epitope peptide

The invention discloses an African swine fever virus T cell epitope peptide for inducing swine T cell immune response and a composition of the African swine fever virus T cell epitope peptide. The amino acid sequence of the African swine fever virus T cell epitope peptide is shown as any one of SEQ ID NO.1-19. Or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1-19 and maintains the protein function shown in SEQ ID NO.1-19 through substitution and / or deletion and / or addition of one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.1-19; the composition comprises amino acids of which the sequences are SEQ ID NO.1-19. A group of ASFV key T cell antigens and epitope peptides are obtained by combining IFN-gamma ELISpot and flow cytometry screening, the ASFV key T cell antigens and epitope peptides can be used as vaccine components to induce strong T cell immune response, and T cells activated by the antigen peptides have the maximum immune protection potential and are essential key antigens for ASFV vaccine research and development.
Owner:YANGZHOU UNIV +1

Pickering emulsion for realizing efficient delivery of immunologic adjuvant monophosphoryl lipid A as well as preparation method and application of Pickering emulsion

The invention provides a Pickering emulsion for realizing high-efficiency delivery of immunologic adjuvant monophosphoryl lipid A. The Pickering emulsion belongs to the technical field of biological medicines and comprises an oil phase, a water phase, monophosphoryl lipid A, polymer nanoparticles and polypeptide antigens, the polymer nanoparticles are dispersed on an oil-water interface of the water phase and the oil phase, and the polypeptide antigens are dispersed on the oil-water interface of the water phase and the oil phase. The monophosphoryl lipid A is stably distributed on an oil-water interface of the water phase and the oil phase in a single molecule form and can flow along the oil-water interface. The Pickering emulsion can realize single-molecule dynamic delivery of the immunologic adjuvant monophosphoryl lipid A, so that the contact and recognition efficiency between the monophosphoryl lipid A and a TLR4 receptor is enhanced, and efficient cellular immune response is induced. The invention also provides a preparation method and application of the Pickering emulsion for realizing efficient delivery of the immunologic adjuvant monophosphoryl lipid A.
Owner:SHENZHEN SECOND PEOPLES HOSPITAL (SHENZHEN INST OF TRANSLATIONAL MEDICINE)

Tubeimoside B liposome as well as preparation method and application thereof

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to tubeimoside B liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving phospholipid, cholesterol and PEGylated phospholipid in an organic solvent to form a mixed solution, and then evaporating the mixed solution to form a film; and hydrating the film by using an aqueous solution of tubeimoside B to finally prepare the tubeimoside B liposome. Compared with free tubeimoside B, the lipidosome has the advantages that the hemolysis percentage is obviously reduced, and antigen-specific humoral immune response and / or cellular immune response can be effectively enhanced when the lipidosome is used as a vaccine adjuvant. In an H1N1 influenza mouse model, the lipidosome combined antigen shows an excellent protection effect, which is shown in that the mouse weight fluctuation is relatively small and the lung virus load is remarkably reduced. The invention provides important theoretical basis and practical examples for developing low-toxicity and high-efficiency plant-derived vaccine adjuvants, and has a wide application prospect.
Owner:ARMY MEDICAL UNIV

Novel adjuvant recombinant herpes zoster vaccine composition as well as preparation and application thereof

PendingCN118924892AImprove the level ofachieve activationAntiviralsAntibody medical ingredientsNucleotideHerpes Zoster Vaccine
The invention relates to the field of biological medicine, in particular to a novel adjuvant recombinant herpes zoster vaccine composition as well as preparation and application thereof. The novel adjuvant recombinant herpes zoster vaccine composition comprises a gE protein antigen and a composite adjuvant, the amino acid sequence of the gE protein antigen is shown as SEQIDN0.1, the composite adjuvant is at least two of an aluminum adjuvant, a squalene oil-in-water adjuvant and a CpG oligodeoxynucleotide adjuvant, and CpG oligodeoxynucleotide is CpG1018. The vaccine composition can significantly improve expression of cytokines such as INF-gamma and IL-2 of mouse CD4 + T cells, improves the immune response level, and can effectively reduce side effects caused by vaccine injection compared with single use of a conventional aluminum adjuvant; and compared with the Qinanlietasuitable researched and developed by GSK, the cell immune response level of the Qinanlietasuitable is relatively improved.
Owner:JIANGSU LEVIESTER BIOTECHNOLOGY CO LTD +1

MRNA vaccine for preventing or treating hepatitis B virus infection and application thereof

The invention belongs to the technical field of biological medicines, and particularly relates to an mRNA vaccine for preventing or treating hepatitis B virus infection and application of the mRNA vaccine. The mRNA vaccine comprises mRNA for coding hepatitis B virus surface antigen or / and hepatitis B virus core associated antigen or / and hepatitis B virus front surface antigen 1 fusion IgG Fc segment protein, and the mRNA is wrapped by lipid nanoparticles to form a delivery system to be prepared into the mRNA vaccine. The vaccine preparation can specifically enhance humoral immune response and cellular immune response aiming at hepatitis B virus surface antigen or / and hepatitis B virus core related antigen or / and hepatitis B virus front surface antigen, and can be used for preventing and treating hepatitis B. All the components in the vaccine preparation can be widely obtained, the vaccine cost is effectively reduced, the vaccine yield is increased, and therefore the vaccine preparation has good practical application value.
Owner:JIANGSU CHUANGYUAN LIFE TECHNOLOGY CO LTD

Recombinant herpes zoster vaccine composition and preparation method thereof

The invention relates to the field of biological medicine, in particular to a recombinant herpes zoster vaccine composition and a preparation method thereof. The recombinant herpes zoster vaccine composition comprises gE protein and an adjuvant, the adjuvant is a squalene oil-in-water adjuvant, and the squalene oil-in-water adjuvant comprises the following components by concentration: 4-5wt% of squalene, 1-5wt% of gE protein, 1-5wt% of gE protein, 1-5wt% of gE protein, 1-5wt% of gE protein, and the balance of water. 0.2 to 0.8 wt% of Tween 80; and 0.2 to 0.8 wt% of Span 85. The vaccine composition disclosed by the invention can specifically enhance cellular immune response aiming at the varicella-zoster virus, can remarkably improve expression of cytokines such as INF-gamma and IL-2 of CD4 + T cells of mice, improves the immune response level of body fluid and cells at the same time, shows high immunocompetence for preventing clinical varicella-zoster virus infection, and has good clinical application prospects. And the components in the vaccine composition are cheap and easy to obtain, so that the vaccine yield is effectively improved, and the vaccine cost is reduced.
Owner:JIANGSU LEVIESTER BIOTECHNOLOGY CO LTD +1

Liposome nano vaccine taking glycyrrhiza polysaccharide as adjuvant as well as preparation method and application of liposome nano vaccine

The invention belongs to the technical field of biological medicines, and provides a lipidosome nano vaccine taking glycyrrhiza polysaccharide as an adjuvant, which comprises a lipidosome shell consisting of phospholipid and cholesterol, and glycyrrhiza polysaccharide and mode antigen OVA257-264 entrapped in a lipidosome core. The invention also provides a preparation method of the liposome nano vaccine taking glycyrrhiza polysaccharide as the adjuvant. The invention also provides an application of the liposome nano vaccine in preparation of antitumor drugs. The lipidosome nano vaccine taking glycyrrhiza polysaccharide as the adjuvant can target lymph nodes, induce an organism to generate cellular immune response and form immune memory, so that the immunotherapy effect on tumors is remarkably enhanced. As a vaccine adjuvant, glycyrrhiza polysaccharide not only has the advantages of being good in biocompatibility, safe and non-toxic, but also can effectively make up for the limitation that a current tumor vaccine adjuvant is low in efficiency, high in toxicity and insufficient in Th1 response.
Owner:SHANGHAI UNIV OF T C M

Veterinary vaccine composite adjuvant as well as preparation method and application thereof

The invention discloses a veterinary vaccine composite adjuvant as well as a preparation method and application thereof. Active ingredients in the vaccine composite adjuvant are a manganese-containing compound and a Mincle agonist. According to the veterinary vaccine composite adjuvant disclosed by the invention, Mn and TDB are combined, so that the immunological enhancement effect of the TDB adjuvant is achieved. The composite adjuvant can induce a strong immune response reaction, significantly improves the immune effect, and is free of residual damage in use. Compared with the H7N9 vaccine prepared by singly using DDA-TDB, the H7N9 vaccine prepared by mixing the H7N9 subtype avian influenza inactivated virus as the antigen with the composite adjuvant can enhance humoral immunity and cellular immune response of a body, reduce virus load and improve protection level, and provides a product and technical support for production of veterinary vaccines.
Owner:YANGZHOU UNIV

Fusion protein IFN alpha-gE-Fc and application thereof in preparation of recombinant varicella-herpes zoster vaccine

The invention belongs to the technical field of biology, and particularly relates to a fusion protein IFN alpha-gE-Fc and application of the fusion protein IFN alpha-gE-Fc in preparation of a recombinant varicella-herpes zoster vaccine. The IFN alpha-gE-Fc fusion protein is constructed, gE is dimerized through the Fc segment of human IgG, the stability and size of the protein can be improved, and effective LN targeting and dendritic cell capture are promoted. In order to further increase the treatment and presentation of DCs on antigens, cell factors IFN alpha are fused at the N end of gE-Fc to induce strong cellular immune response and humoral immunity at the same time, no exogenous sequence is introduced, cellular immune response can be effectively enhanced, the defects of traditional adjuvants are overcome, and the immunologic adjuvant has a good application prospect. A candidate vaccine is provided for developing a safe and effective herpes zoster vaccine.
Owner:INST OF MICROBIOLOGY CHINESE ACAD OF SCI

Preparation and application of pseudorabies virus circular RNA (Ribonucleic Acid) molecule

The invention discloses preparation and application of pseudorabies virus circular RNA (Ribonucleic Acid). The circular RNA comprises a coding element for coding any one of gD protein, gB protein, gC protein and gK protein of the pseudorabies virus; preferably, the coding element encodes a pseudorabies virus gD protein. Further, the encoding element encodes gD wild-type protein, gD truncated protein, gD mutant protein and gD truncated mutant protein; preferred coding elements encode gD truncated plus muteins. Further, the encoding element encodes an optimized nucleotide sequence of pseudorabies virus gD truncated and mutant protein. Further, the circular RNA comprises an optimized translation initiation element. Researches show that the circular RNA provided by the invention can induce protein expression in an animal body, generate a high-level neutralizing antibody and successfully activate T cell immunity, especially CD8 + T cell immune response, and a basis is provided for preparing a circular mRNA vaccine for preventing and / or treating pseudorabies.
Owner:SHANGHAI SHENRAY UNITED BIOMEDICAL CO LTD

Use of tRNA in promoting protein coding ability of mRNA

The invention relates to an application of tRNA (transfer ribonucleic acid) in promoting the protein coding capability of mRNA (messenger ribonucleic acid), the expression level of target protein is improved by overexpressing the tRNA, and a codon corresponding to the tRNA can promote or improve the stability of the mRNA. The invention also provides a novel tRNA + mRNA immune enhanced vaccine, and the antigen protein coding capability of the mRNA vaccine is enhanced by introducing one or more tRNA molecules, so that stronger humoral immunity and cellular immunity responses are aroused in vivo. The invention also provides a recombinant cell for producing the antibody, the recombinant cell overexpresses the tRNA capable of improving the expression quantity of the antibody, and the tRNA comprises a tRNA isodecoder family. The invention also provides a recombinant cell for producing or packaging the recombinant AAV. The recombinant cell is characterized in that the recombinant cell overexpresses tRNA capable of improving the packaging efficiency of the AAV.
Owner:PEKING UNIV

A novel coronavirus nano-vaccine with targeted synergistic enhancement

The present invention discloses a novel coronavirus nano-vaccine with targeted synergistic effect, belonging to the field of vaccines. The active ingredient of the vaccine is a fusion protein, which includes the amino acid sequence of the RBD domain of the novel coronavirus. The N-terminus of the amino acid sequence of the RBD domain is connected to XCL1 through a flexible linker GSG, and the C-terminus of the RBD domain sequence is connected to the Ferritin protein through a flexible linker GSG. The purified XCL1-RBD-Ferritin can be assembled into nanoparticles of 24-mers, improving the efficiency of RBD antigen in activating DCs, especially DC1s, thereby efficiently initiating humoral and cellular immune responses.
Owner:GUANGDONG PHARMA UNIV

Nanoparticle vaccine for mucosal immunity as well as preparation method and application of nanoparticle vaccine

The invention relates to a nanoparticle vaccine for mucosal immunity and a preparation method and application thereof. The nanoparticle is of a core-shell structure, the core is a compound with a hydrophobic group, the shell is maltodextrin, and the surface of the shell is loaded with a conjugate of an antigen protein coupled cationic polymer and an adjuvant. The prepared nano-particle vaccine can be used for mucosal immunity, co-delivery of a vaccine adjuvant and high-molecular-weight antigen protein is achieved, mucosal immune response of a body can be remarkably enhanced, meanwhile, strong systemic humoral immunity and cellular immune response can be induced, and the nano-particle vaccine is uniform in particle size and good in dispersity.
Owner:INSTITUTE OF PROCESS ENGINEERING CHINESE ACADEMY OF SCIENCES

Monoclonal cell for expressing HPV (human papilloma virus) 18 type E6 protein and application of monoclonal cell in construction of HPV tumor animal model

The invention discloses a monoclonal cell for expressing HPV (human papilloma virus) 18 type E6 protein and application of the monoclonal cell in construction of an HPV tumor animal model, and relates to the technical field of HPV tumor animal models. A monoclonal cell which can stably express target protein and is good in tumor formation effect is obtained through a limited dilution method and single cell imaging sorting identification, and after an animal model is inoculated with the medicine or vaccine composition, the medicine or vaccine composition has an obvious inhibition effect on tumors; an animal model can be induced to generate high-level humoral immunity, and high-level specific CD4 + T cell and CD8 + T cell immune response can be generated. Compared with a TC-1 cell, the monoclonal cell provided by the invention has more remarkable tumorigenicity and can better mediate the growth of tumors in animals. The monoclonal cell obtained by screening has a good application prospect in screening a pharmaceutical composition or a vaccine composition for preventing and / or treating HPV, and can be used for evaluating a therapeutic vaccine for targeting HPV18.
Owner:CHENGDU MAXVAX BIOTECHNOLOGY LLC +1

Microcapsule vaccine delivery system based on nano-vesicles as well as preparation method and application of microcapsule vaccine delivery system

The invention provides a microcapsule vaccine delivery system based on nano-vesicles and a preparation method and application thereof, and relates to the technical field of biological medicine, an inner core of the vaccine delivery system is a nano-compound, and the nano-compound is a compound of bacterial-derived nano-vesicles and antigens; the outer layer of the nano-composite is coated with a calcium alginate layer and a chitosan layer. The preparation method of the microcapsule vaccine delivery system based on the nano vesicles is simple and rapid, can be applied to preparation of various types of vaccines, and realizes co-delivery of antigens, adjuvants and multivalent antigens. The prepared micro-nano fusion system used as the oral vaccine carrier can induce humoral immune response, cellular immune response and mucosal immune response at the same time.
Owner:SICHUAN UNIV

Brucella recombinant adenovirus based on antigen epitopes of CU / ZN-SOD, BP26 and OMP31 and application of Brucella recombinant adenovirus

The invention belongs to the technical field of vaccine preparation, and particularly relates to a Brucella recombinant adenovirus based on antigen epitopes of CU / ZN-SOD, BP26 and OMP31 and application of the Brucella recombinant adenovirus, and the nucleotide sequence of the Brucella recombinant adenovirus is shown as SEQ ID NO: 1. The recombinant adenovirus provided by the invention can induce high-level cellular immune response level and humoral immune response level, which are biased to Th1 type immune response, and in addition, the recombinant adenovirus is high in immune safety.
Owner:SHIHEZI UNIVERSITY

African swine fever mRNA vaccine composition capable of synergistically activating and enhancing humoral immunity and cellular immunity and application thereof

The invention discloses an African swine fever mRNA vaccine composition capable of synergistically activating and enhancing humoral immunity and cellular immunity and application of the African swine fever mRNA vaccine composition, and belongs to the technical field of biological medicines. Specifically, a plurality of key antigen proteins of the African swine fever virus are used as target spots and are connected in series through connexons to form single-chain mRNA, so that multiple immunogens can be translated from the same transcript, and multiple antibodies are induced to be generated at the same time; a conservative recombinant T cell immunogen capable of activating cellular immune response is introduced, so that the cellular immune response can be enhanced, the ADE risk can be reduced, and the cross protection capability can also be improved; in addition, a molecular adjuvant IL-12 is added into the mRNA vaccine to enhance the immune response of the African swine fever vaccine, so that stronger immune protection efficacy is induced.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV

Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions

The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and / or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
Owner:INST PASTEUR +1

A CD4 helper t cell epitope fusion peptide and vaccine thereof

The present application provides a CD4 helper T cell epitope fusion peptide, its encoding nucleic acid and an immune composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope. The epitope fusion peptide provided by the present application can greatly improve the cellular immune response level of the target immunogen, especially a weak immunogen, and is an effective means to overcome the immune system's immune tolerance to antigens, especially tumor antigens or infection-related antigens, and is suitable for efficiently enhancing the efficacy of vaccines.
Owner:VACDIAGN BIOTECH

SARS-CoV-2 fusion protein vaccine / regimen

A SARS-CoV-2 immunotherapeutic targeted fusion protein regimen or vaccine in which the extracellular domain (ecd) of the CD40L immunostimulatory protein, is attached individually to mRNA encoding a Selected Fragment of the Spike Protein (SFSP), representing a different functional feature and a different domain or domain region, or both of the Spike Protein, to generate 7 distinct SFSP / ecdCD40L translation units, each translation unit being converted into a SFSP / ecdCD40L fusion protein regimen or vaccine and all combined into a single fusion protein mixture or composition for injection, preferably inter-muscularly (im). Each fragment or peptide is designed to activate a humoral and cellular immune response to a different SFSP. Each SFSP fragment or peptide, as a vaccine strategy for the SARS-CoV-2 virus, has the capability to suppress the emergence of immunological escape mutants. The fusion protein mixture or composition of multiple fragments or peptides could be incorporated in any one of several delivery platforms such as an adenoviral expression vector or an mRNA platform.
Owner:MICROVAX LLC

A kind of avian pathogenic Escherichia coli antigen multi-epitope fusion protein and its preparation method and application

The invention discloses a preparation method and application of a hexavalent multi-epitope fusion protein of avian pathogenic Escherichia coli. The invention preferably selects antigenic epitopes of the curli fimbriae subunit CsgA, lipoprotein SlyB, maltose porin LamB, outer membrane protein PhoE, proteolytic enzyme activator NlpD and lipoprotein Pal main structural subunit of avian pathogenic Escherichia coli, and preferably connects with the heat-labile enterotoxin LTb fusion protein in series to construct an antigenic multi-epitope fusion protein of six proteins of avian pathogenic Escherichia coli. The antigenic multi-epitope fusion protein has a wide serotype coverage, is non-allergenic, has strong immunogenicity, and produces strong specific humoral immunity and cellular immune response after immunizing animals.
Owner:SHANGHAI VETERINARY RESEARCH INSTITUTE CAAS (CHINESE ANIMAL HEALTH & EPIDEMIOLOGY CENTER SHANGHAI BRANCH)

A varicella-zoster virus vaccine and uses thereof

The application provides a varicella-zoster virus vaccine and application thereof, and belongs to the technical field of vaccines.The varicella-zoster virus vaccine comprises liposome nanoparticles, zoster virus glycoprotein E and an adjuvant encapsulated in the liposome nanoparticles.The adjuvant comprises triterpenoid saponins.In the application, the zoster virus glycoprotein E (gE) is wrapped by the liposome nanoparticles, which can effectively promote antigen-presenting cells to phagocytose and efficiently deliver the antigen, and realize sustained stimulation of the vaccine to the body to produce a specific cellular immune response against VZV-gE.The triterpenoid saponins used in the application can effectively realize cross-presentation of the antigen zoster virus glycoprotein E and induce an antigen-specific cellular immune response.In addition, the cholesterol rich in the liposome nanoparticles can effectively neutralize the cytotoxicity of the triterpenoid saponins, ensuring the safety of the vaccine.
Owner:TAIZHOU BIVO BIOTECH CO LTD